TOLREMO is a cutting-edge biotechnology company founded in 2017 as an ETH Zurich Spin-off. With a focus on cancer treatment, TOLREMO combines the founders' extensive knowledge of the molecular mechanisms of cancer and drug resistance with expertise in medicinal chemistry and pharmaceutical drug development. At TOLREMO, our mission is to make cancer a minor matter by developing resistance-preventing combination therapies.

Our drug candidates are designed to enhance standard cancer treatments, providing better response rates, longer survival, and an improved quality of life for patients. We also explore the potential of our drug candidates as stand-alone agents in specific cancer indications. Driven by our expertise in non-mutational drug resistance, we pioneer new precision therapies to prevent resistance in cancer patients.

Our drug development programs leverage novel transcriptome-based bioinformatics strategies to guide preclinical translation and clinical development. With deep knowledge in assay development, high-throughput screening, image analysis algorithms, medicinal chemistry, and bioinformatics, we have established a robust platform to identify drug resistance regulators and develop small molecule therapies against promising drug targets. TOLREMO is headquartered in greater Basel, a renowned biotech-hub in Europe, and a spin-off of the prestigious ETH Zurich university.

Join us in our pursuit to revolutionize cancer treatment and make a difference in patients' lives